CY1112635T1 - 1-[2-(2,4-διμεθυλφαινυλσουλφανυλ)-φαινυλ]πιπεραζινη ως μια ενωση με συνδυασμενη δραστικοτητα επαναπροσληψης σεροτονινης, 5-ητ3 και 5-ητ1α για τη θεραπεια γνωστικης εξασθενησης - Google Patents

1-[2-(2,4-διμεθυλφαινυλσουλφανυλ)-φαινυλ]πιπεραζινη ως μια ενωση με συνδυασμενη δραστικοτητα επαναπροσληψης σεροτονινης, 5-ητ3 και 5-ητ1α για τη θεραπεια γνωστικης εξασθενησης

Info

Publication number
CY1112635T1
CY1112635T1 CY20121100240T CY121100240T CY1112635T1 CY 1112635 T1 CY1112635 T1 CY 1112635T1 CY 20121100240 T CY20121100240 T CY 20121100240T CY 121100240 T CY121100240 T CY 121100240T CY 1112635 T1 CY1112635 T1 CY 1112635T1
Authority
CY
Cyprus
Prior art keywords
serotonin
dimethylphenylsulfanyl
phenyl
piperazine
compound
Prior art date
Application number
CY20121100240T
Other languages
Greek (el)
English (en)
Inventor
Benny Bang-Andersen
André Faldt
Arne Mørk
De Diego Heidi Lopez
René Holm
Tine Bryan Stensbøl
Lone Munch Ringgaard
Michael J Mealy
Michael Harold Rock
Jørgen Brodersen
Morten Jørgensen
Nicholas Moore
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112635(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1112635T1 publication Critical patent/CY1112635T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
CY20121100240T 2006-06-16 2012-03-08 1-[2-(2,4-διμεθυλφαινυλσουλφανυλ)-φαινυλ]πιπεραζινη ως μια ενωση με συνδυασμενη δραστικοτητα επαναπροσληψης σεροτονινης, 5-ητ3 και 5-ητ1α για τη θεραπεια γνωστικης εξασθενησης CY1112635T1 (el)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US80501406P 2006-06-16 2006-06-16
DKPA200600824 2006-06-16
US82666606P 2006-09-22 2006-09-22
DKPA200601223 2006-09-22
US86282606P 2006-10-25 2006-10-25
DKPA200601384 2006-10-25
DKPA200700427 2007-03-20
EP07764495.3A EP2044043B2 (en) 2006-06-16 2007-06-15 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment

Publications (1)

Publication Number Publication Date
CY1112635T1 true CY1112635T1 (el) 2016-02-10

Family

ID=39722479

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100240T CY1112635T1 (el) 2006-06-16 2012-03-08 1-[2-(2,4-διμεθυλφαινυλσουλφανυλ)-φαινυλ]πιπεραζινη ως μια ενωση με συνδυασμενη δραστικοτητα επαναπροσληψης σεροτονινης, 5-ητ3 και 5-ητ1α για τη θεραπεια γνωστικης εξασθενησης

Country Status (31)

Country Link
US (13) US8722684B2 (OSRAM)
EP (2) EP2044043B2 (OSRAM)
JP (8) JP4590013B2 (OSRAM)
KR (3) KR101627901B1 (OSRAM)
CN (3) CN102614179B (OSRAM)
AR (1) AR061481A1 (OSRAM)
AT (1) ATE540941T1 (OSRAM)
AU (1) AU2007260355B2 (OSRAM)
BR (3) BR122020011920A2 (OSRAM)
CA (1) CA2655212C (OSRAM)
CL (1) CL2011001610A1 (OSRAM)
CY (1) CY1112635T1 (OSRAM)
DK (1) DK2044043T4 (OSRAM)
EA (1) EA015287B1 (OSRAM)
ES (2) ES2379200T5 (OSRAM)
FI (1) FI2044043T5 (OSRAM)
HR (1) HRP20120173T4 (OSRAM)
IL (1) IL195511A (OSRAM)
MA (1) MA30575B1 (OSRAM)
MX (1) MX2008016141A (OSRAM)
MY (1) MY150647A (OSRAM)
NO (1) NO343929B3 (OSRAM)
NZ (1) NZ572986A (OSRAM)
PL (1) PL2044043T5 (OSRAM)
PT (1) PT2044043E (OSRAM)
RS (1) RS52205B2 (OSRAM)
SI (1) SI2044043T2 (OSRAM)
TN (1) TNSN08460A1 (OSRAM)
TW (1) TWI443091B (OSRAM)
WO (1) WO2007144005A1 (OSRAM)
ZA (1) ZA200810017B (OSRAM)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EA015287B1 (ru) * 2006-06-16 2011-06-30 Х. Лундбекк А/С 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нти 5-нтдля лечения когнитивного нарушения
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
BRPI1015338C1 (pt) * 2009-04-24 2021-08-10 H Lundbeck As formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento
BR112012003280A2 (pt) * 2009-08-24 2017-05-23 H Lundbeck As composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BR112012027794A2 (pt) * 2010-04-30 2016-08-02 Takeda Pharmaceutical tablete entérico
EP3650439B1 (en) * 2010-07-23 2021-02-24 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
BR112014016322B8 (pt) * 2012-01-03 2020-12-01 H Lundbeck As processo para a preparação de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina
WO2014042945A1 (en) * 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
EP2897943B1 (en) 2012-09-19 2019-04-24 Sandoz AG Crystalline form of vortioxetine hydrobromide
PE20151026A1 (es) * 2012-12-13 2015-07-11 Lundbeck & Co As H Composiciones que comprenden vortioxetina y donepezilo
CN104995181B (zh) * 2013-02-22 2017-03-08 H.隆德贝克有限公司 沃替西汀生产方法
TR201906691T4 (tr) 2013-04-04 2019-05-21 Lek Pharmaceuticals 1-(2-((2,4-dimetilfenil)tiyo)fenil)piperazinin sentezine yönelik yeni proses.
WO2014177491A1 (en) 2013-04-29 2014-11-06 Lek Pharmaceuticals D.D. New solid form of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide
CN105339361A (zh) * 2013-05-31 2016-02-17 斯洛文尼亚莱柯制药股份有限公司 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
AU2014286308B2 (en) * 2013-07-01 2018-05-10 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
IN2013MU03121A (OSRAM) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
CN104650003A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种沃替西汀化合物
EP2878596A1 (en) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN103788020B (zh) * 2014-01-22 2015-11-04 苏州明锐医药科技有限公司 沃替西汀的制备方法
EA029060B1 (ru) * 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
AU2015227296A1 (en) * 2014-03-05 2016-09-08 Takeda Pharmaceutical Company Limited Method for treating depression and major depressive disorder
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104974110A (zh) * 2014-04-10 2015-10-14 江苏豪森药业股份有限公司 1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪氢溴酸盐的新晶型及其制备方法和用途
EP3137083A2 (en) * 2014-04-28 2017-03-08 Alembic Pharmaceuticals Limited Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
CN105254590B (zh) * 2014-05-09 2019-09-03 江苏豪森药业集团有限公司 沃替西汀氢溴酸盐晶型及其制备方法和用途
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105198837B (zh) * 2014-06-09 2018-05-04 上海医药工业研究院 一种沃替西汀氢溴酸盐晶体及其制备方法
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN105330614A (zh) * 2014-08-04 2016-02-17 上海诺星医药科技有限公司 一种氢溴酸沃替西汀晶体及其制备方法
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
US20170333424A1 (en) * 2014-10-24 2017-11-23 Hexal Ag Amorphous Vortioxetine Hydrobromide
CN105669594A (zh) * 2014-11-19 2016-06-15 康普药业股份有限公司 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104356092B (zh) * 2014-11-27 2017-03-22 合肥创新医药技术有限公司 沃替西汀的制备方法
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN105777667A (zh) * 2014-12-18 2016-07-20 康普药业股份有限公司 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法
CN105801517A (zh) * 2014-12-30 2016-07-27 上海奥博生物医药技术有限公司 一种沃替西汀氢溴酸盐新晶型及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN104644594A (zh) * 2015-02-03 2015-05-27 郑州大明药物科技有限公司 一种氢溴酸沃替西汀胃溶片及其制备方法
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3262031A1 (en) 2015-02-25 2018-01-03 Lupin Limited Process for the preparation of vortioxetine
CN104650004B (zh) * 2015-03-06 2017-06-06 中山万汉制药有限公司 一种氢溴酸沃替西汀的制备方法
CN104628677A (zh) * 2015-03-16 2015-05-20 浙江大学 一种沃替西汀有机酸盐晶型及其制备方法
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN105367515B (zh) * 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN104910099B (zh) * 2015-05-22 2017-03-08 扬子江药业集团有限公司 一种氢溴酸沃替西汀晶体的制备方法
CN106316986B (zh) * 2015-07-03 2019-02-05 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪氢溴酸盐α型晶体的制备方法
CN105111167A (zh) * 2015-08-06 2015-12-02 华南理工大学 一种沃替西汀半盐酸盐及其制备方法和药物组合物
CN105061364A (zh) * 2015-08-17 2015-11-18 河北国龙制药有限公司 氢溴酸沃替西汀的制备方法
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
CN105153066B (zh) * 2015-09-07 2018-01-09 浙江大学 盐酸沃替西汀的结晶型物及其制备方法
CN106632145B (zh) * 2015-11-04 2021-11-05 江苏豪森药业集团有限公司 沃替西汀氢溴酸盐晶型α的新制备方法
CN106674153A (zh) * 2015-11-05 2017-05-17 浙江京新药业股份有限公司 沃替西汀半盐酸盐晶体及其组合物与制备和应用
CN105294554B (zh) * 2015-11-18 2017-11-07 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
GB2557867A (en) * 2015-11-18 2018-07-04 Azad Pharmaceutical Ingredients Ag New synthetic path to vortioxetine salts
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
EP3184104B1 (en) 2015-12-23 2018-09-12 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
US20190194154A1 (en) * 2016-01-20 2019-06-27 Amneal Pharmaceuticals Company Gmbh Polymorphic Forms Of Vortioxetine Hydrobromide Tert-Butanolate
WO2017154016A1 (en) * 2016-03-07 2017-09-14 Msn Laboratories Private Limited Novel crystalline polymorphs of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide and process for preparation thereof
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
CA3018402C (en) * 2016-03-29 2021-05-11 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Vortioxetine pamoic acid salt and crystal form thereof
WO2017215636A1 (zh) * 2016-06-16 2017-12-21 广东东阳光药业有限公司 二芳基硫醚哌嗪类化合物及其制备方法和用途
KR20190025556A (ko) * 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
WO2018011382A1 (en) * 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
CN106243062A (zh) * 2016-07-31 2016-12-21 合肥远志医药科技开发有限公司 一种沃替西汀工业化生产方法
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
WO2018065348A1 (en) 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3585388A4 (en) * 2017-02-23 2020-08-12 Unichem Laboratories Ltd IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE BROMHYDRATE
PT3615518T (pt) * 2017-04-25 2022-02-14 H Lundbeck As Processo de fabrico da forma alfa da vortioxetina hbr
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN109503517A (zh) * 2017-09-14 2019-03-22 万全万特制药（厦门）有限公司 一种沃替西汀α晶型的制备方法
JP6876586B2 (ja) * 2017-09-27 2021-05-26 Ｔｏｗａ株式会社 加工装置
CN109928941A (zh) * 2017-12-19 2019-06-25 成都弘达药业有限公司 一种氢溴酸沃替西汀的结晶化合物及其制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
US10111873B1 (en) 2018-01-17 2018-10-30 King Saud University Dihydropyrimidinone derivatives
EP3762371A1 (en) * 2018-02-06 2021-01-13 Piramal Enterprises Limited An improved process for the preparation of vortioxetine and salts thereof
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109535050A (zh) * 2018-12-14 2019-03-29 合肥创新医药技术有限公司 一种1,2-双（（2,4-二甲基苯基）硫基）苯的制备方法
CA3146024A1 (en) 2019-09-04 2021-03-11 Seasons Biotechnology (Taizhou) Co., Ltd. Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
TR202001040A2 (tr) * 2020-01-23 2021-07-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorti̇okseti̇n hi̇drobromi̇di̇n kri̇stali̇n c formu
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
KR102455000B1 (ko) 2020-07-06 2022-10-17 원광대학교산학협력단 피페라진 화합물 및 이의 제조 방법
CN112006995A (zh) * 2020-08-14 2020-12-01 石药集团中奇制药技术（石家庄）有限公司 一种氢溴酸伏硫西汀片的制备方法
CN114075154B (zh) * 2020-08-20 2025-03-28 正大天晴药业集团股份有限公司 伏硫西汀的制备方法
WO2022052391A1 (zh) 2020-09-10 2022-03-17 苏州富德兆丰生化科技有限公司 伏硫西汀的合成方法
CN112125868B (zh) * 2020-09-25 2021-08-03 中山万远新药研发有限公司 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
CN116836132A (zh) * 2022-03-23 2023-10-03 浙江华海药业股份有限公司 一种沃替西汀氢溴酸盐晶型h及其制备方法和用途
CN115160258B (zh) * 2022-06-24 2023-11-17 辰欣药业股份有限公司 一种氢溴酸沃替西汀γ晶型的制备方法
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
JP7632902B2 (ja) 2023-02-10 2025-02-19 株式会社Dhq タキシフォリン含有組成物
CN116589434A (zh) * 2023-05-22 2023-08-15 山东泰合医药科技有限公司 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
CA2157190A1 (en) 1993-03-05 1994-09-15 Wilfried Fischer Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
JPH07110050A (ja) 1993-10-13 1995-04-25 Daikin Mfg Co Ltd 捩じり振動減衰装置
HU226635B1 (en) 1995-01-23 2009-05-28 Asubio Pharma Co Piperidine and piperazine derivatives, medicines containing them as active ingredient and their use
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
UA78181C2 (en) 1998-05-22 2007-03-15 Lilly Co Eli Combined therapy for treating refractory depressive states
ATE360634T1 (de) 1998-07-10 2007-05-15 Massachusetts Inst Technology Ligande für metalle und verbesserte metall- katalysierte verfahren, die darauf basieren
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
EP1246816B1 (en) 1999-12-30 2004-03-17 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
MXPA03004714A (es) 2000-11-28 2003-08-19 Pfizer Prod Inc Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MXPA04005989A (es) * 2001-12-20 2004-09-27 Lundbeck & Co As H Derivados de ariloxifenilo y arilsulfanilfenilo.
KR101255356B1 (ko) 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
DK1626720T3 (da) 2003-04-04 2008-12-01 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
WO2005094896A2 (en) 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
CN101098850B (zh) 2005-01-06 2010-09-15 Cj第一制糖株式会社 西布曲明的无机酸盐
CN1270776C (zh) 2005-05-08 2006-08-23 纪辉 治疗粘膜溃疡的药物组合物，其制备和用途
US8299095B2 (en) 2006-06-16 2012-10-30 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof
EA015287B1 (ru) * 2006-06-16 2011-06-30 Х. Лундбекк А/С 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нти 5-нтдля лечения когнитивного нарушения
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200938194A (en) 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
EP2897943B1 (en) 2012-09-19 2019-04-24 Sandoz AG Crystalline form of vortioxetine hydrobromide

Also Published As

Publication number Publication date
NZ572986A (en) 2012-02-24
KR101445514B1 (ko) 2014-09-29
NO20090229L (no) 2009-02-12
NO343929B1 (no) 2019-07-08
US20140248356A1 (en) 2014-09-04
ES2432102T3 (es) 2013-11-29
US8969355B2 (en) 2015-03-03
SI2044043T2 (sl) 2021-04-30
EA200970018A1 (ru) 2009-06-30
JP2025021476A (ja) 2025-02-13
CL2011001610A1 (es) 2011-10-14
IL195511A (en) 2014-03-31
US20140315921A1 (en) 2014-10-23
FI2044043T3 (OSRAM) 2012-03-30
TWI443091B (zh) 2014-07-01
JP5702929B2 (ja) 2015-04-15
US20180333408A1 (en) 2018-11-22
JP4590013B2 (ja) 2010-12-01
US20160083359A1 (en) 2016-03-24
US20150005318A1 (en) 2015-01-01
ES2379200T5 (es) 2021-10-20
MX2008016141A (es) 2009-02-04
BRPI0713425A2 (pt) 2012-03-13
US11458134B2 (en) 2022-10-04
RS52205B2 (sr) 2021-05-31
KR20090028712A (ko) 2009-03-19
CN102617513A (zh) 2012-08-01
US9861630B1 (en) 2018-01-09
JP2023009175A (ja) 2023-01-19
US9125909B2 (en) 2015-09-08
JP2017008086A (ja) 2017-01-12
IL195511A0 (en) 2009-09-01
AU2007260355B2 (en) 2013-08-15
CA2655212A1 (en) 2007-12-21
US9125908B2 (en) 2015-09-08
EP2044043B1 (en) 2012-01-11
CA2655212C (en) 2012-07-31
JP6724082B2 (ja) 2020-07-15
US20100297240A1 (en) 2010-11-25
MA30575B1 (fr) 2009-07-01
FI2044043T5 (fi) 2023-11-21
US9095588B2 (en) 2015-08-04
HK1172014A1 (en) 2013-04-12
KR101627901B1 (ko) 2016-06-13
ES2379200T3 (es) 2012-04-23
JP2009541216A (ja) 2009-11-26
ZA200810017B (en) 2010-04-28
US9125910B2 (en) 2015-09-08
JP2015157872A (ja) 2015-09-03
HRP20120173T4 (hr) 2021-04-16
BR122020011899B1 (pt) 2021-05-11
US9101626B2 (en) 2015-08-11
CN102614179A (zh) 2012-08-01
JP6101742B2 (ja) 2017-03-22
KR20130079619A (ko) 2013-07-10
US20140371453A1 (en) 2014-12-18
SI2044043T1 (sl) 2012-04-30
PL2044043T5 (pl) 2022-05-02
US8722684B2 (en) 2014-05-13
US20140248355A1 (en) 2014-09-04
US20200163959A1 (en) 2020-05-28
CN101472906B (zh) 2012-04-25
KR20130133078A (ko) 2013-12-05
HK1171951A1 (en) 2013-04-12
RS52205B (sr) 2012-10-31
US20170360777A1 (en) 2017-12-21
MY150647A (en) 2014-02-14
NO343929B3 (no) 2019-07-08
DK2044043T3 (da) 2012-03-19
TW200817340A (en) 2008-04-16
CN102617513B (zh) 2015-09-23
JP2010090165A (ja) 2010-04-22
HRP20120173T1 (en) 2012-03-31
DK2044043T4 (da) 2021-04-12
JP2018199689A (ja) 2018-12-20
JP2013056933A (ja) 2013-03-28
EA015287B1 (ru) 2011-06-30
AR061481A1 (es) 2008-08-27
PL2044043T3 (pl) 2012-06-29
ATE540941T1 (de) 2012-01-15
CN102614179B (zh) 2015-11-25
EP2439201A1 (en) 2012-04-11
CN101472906A (zh) 2009-07-01
HK1134483A1 (en) 2010-04-30
EP2439201B1 (en) 2013-08-07
EP2044043B2 (en) 2021-03-03
PT2044043E (pt) 2012-03-26
AU2007260355A1 (en) 2007-12-21
US20140377363A1 (en) 2014-12-25
US20230021520A1 (en) 2023-01-26
EP2044043A1 (en) 2009-04-08
BR122020011920A2 (pt) 2020-08-25
WO2007144005A1 (en) 2007-12-21
TNSN08460A1 (en) 2010-04-14
JP5763609B2 (ja) 2015-08-12
US9227946B2 (en) 2016-01-05
US20140256943A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
CY1112635T1 (el) 1-[2-(2,4-διμεθυλφαινυλσουλφανυλ)-φαινυλ]πιπεραζινη ως μια ενωση με συνδυασμενη δραστικοτητα επαναπροσληψης σεροτονινης, 5-ητ3 και 5-ητ1α για τη θεραπεια γνωστικης εξασθενησης
EP4328217A4 (en) CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING IT AND ITS USE
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
CL2008002622A1 (es) 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
CY1111530T1 (el) Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης για τη χρηση σαν ενεργο συστατικο σε φαρμακευτικες συνθεσεις
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1105014T1 (el) Ο συνδυασμος ενος αναστολεα επαναπροσληψης σεροτονινης κι ενος 5-ht2c ανταγωνιστη, αντιστροφου αγωνιστη ή μερικου αγωνιστη
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
ECSP045482A (es) Inhibidores de la 11-beta-hydroxiesteroide deshidrogenasa 1 para el tratamiento de la diabetes, obesidad y dislipidemia
CY1113154T1 (el) Συνδυασμος του αναληπτικου modafinil και ενος αντικαταθλιπτικου για τη θεραπεια της καταθλιψης
EP1941060A4 (en) PROTEIN DEMETHYLASES WITH A JMJC DOMAIN
TW200715969A (en) Fungicidal active-compound combination
NO20052487D0 (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
SV2005001805A (es) 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735
CL2007003044A1 (es) Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
ECSP045145A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo
CY1110796T1 (el) Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
RU2003110288A (ru) Вещество, обладающее антидепрессивной активностью
CL2007003842A1 (es) Procedimiento para la produccion de una pelicula de celulosa, utilizable para la cobertura y la regeneracion de lesiones cutaneas y tisulares, mediante el cultivo de acetobacter xylinum y al menos un microorganismo del genero leuconostoc; y dicha pel
DE602006013953D1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
BRPI0409511A (pt) composto, composição farmacêutica, e, uso do composto
TH97668A (th) สารประกอบที่มีฤทธิ์ร่วมกันของ sert, 5-ht3 และ 5-ht1a